Patent · US Active

Methods of use of soluble CD24 for therapy of rheumatoid arthritis

US10793617B2 · kind B2 · utility

0Cited by
4References
14Claims
0Family size

Assignee

Inventors

Key dates

Filing dateAug 16, 2018
Grant dateOct 6, 2020
Priority date
Expiry dateAug 16, 2038

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC07K2319/30
  • WIPO fieldBiotechnology
  • WIPO sectorChemistry

Abstract

Provided herein is a CD24 protein. The CD24 protein may include mature human or mouse CD24, as well as a N- or C-terminally fused portion of a mammalian immunoglobulin.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.